Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AXSM Stock Summary
Top 10 Correlated ETFs
AXSM
In the News
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial
Axsome Therapeutics said on Monday its therapy for a sleep disorder met the main goal of a late-stage study.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20 a.m. Eastern Time at the Fontainebleau in Miami Beach, Florida.
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, from 9:50-10:20 a.m. Eastern Time at the Marriott Copley Place in Boston, Massachusetts.
3 Biotech Stocks to Buy and Hold for the Next 10 Years
CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
AXSM Financial details
AXSM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 1.23 | 5.96 | |
Net income per share | -2.05 | -2.83 | -3.59 | -4.86 | -5.27 | |
Operating cash flow per share | -1.36 | -2.11 | -2.88 | -2.87 | -3.19 | |
Free cash flow per share | -1.36 | -2.11 | -2.89 | -2.88 | -3.21 | |
Cash per share | 6.47 | 4.94 | 2.3 | 4.94 | 8.5 | |
Book value per share | -5.17 | -7.49 | -10.88 | 2.69 | 4.2 | |
Tangible book value per share | 5.25 | 3.06 | -10.88 | 0.97 | 2.77 | |
Share holders equity per share | -5.17 | -7.49 | -10.88 | 2.69 | 4.2 | |
Interest debt per share | 0.62 | 1.42 | 1.47 | 2.51 | 4.09 | |
Market cap | 3.52B | 3.03B | 1.42B | 3.14B | 3.62B | |
Enterprise value | 3.32B | 2.9B | 1.38B | 3.03B | 3.42B | |
P/E ratio | -50.46 | -28.76 | -10.53 | -15.86 | -15.11 | |
Price to sales ratio | 0 | 0 | 0 | 62.67 | 13.36 | |
POCF ratio | -75.82 | -38.64 | -13.13 | -26.91 | -24.92 | |
PFCF ratio | -75.8 | -38.61 | -13.09 | -26.75 | -24.82 | |
P/B Ratio | -19.99 | -10.87 | -3.47 | 28.62 | 18.93 | |
PTB ratio | -19.99 | -10.87 | -3.47 | 28.62 | 18.93 | |
EV to sales | 0 | 0 | 0 | 60.55 | 12.62 | |
Enterprise value over EBITDA | -49.42 | -29.24 | -11.1 | -17.72 | -19.4 | |
EV to operating cash flow | -71.51 | -36.93 | -12.79 | -26 | -23.54 | |
EV to free cash flow | -71.49 | -36.91 | -12.76 | -25.85 | -23.45 | |
Earnings yield | -0.02 | -0.03 | -0.09 | -0.06 | -0.07 | |
Free cash flow yield | -0.01 | -0.03 | -0.08 | -0.04 | -0.04 | |
Debt to equity | -0.11 | -0.18 | -0.12 | 0.86 | 0.94 | |
Debt to assets | 0.09 | 0.27 | -0.15 | 0.29 | 0.3 | |
Net debt to EBITDA | 2.98 | 1.35 | 0.29 | 0.62 | 1.13 | |
Current ratio | 9 | 7.85 | 3.75 | 2.54 | 3.63 | |
Interest coverage | -54.25 | -38.64 | -21.89 | -24.06 | -28.34 | |
Income quality | 0.68 | 0.76 | 0.83 | 0.62 | 0.61 | |
Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
Payout ratio | 0 | 0 | 0 | -0.22 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 1.16 | 0.36 | |
Intangibles to total assets | 0 | 0 | 0 | 0.21 | 0.11 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.01 | 0 | |
Capex to depreciation | -0.43 | -0.59 | -0.27 | -0.13 | -0.09 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.75 | 0.23 | |
Graham number | 15.44 | 21.85 | 29.63 | 17.17 | 22.32 | |
ROIC | 0.44 | 0.45 | 0.36 | -0.91 | -0.49 | |
Return on tangible assets | -0.32 | -0.57 | 0.4 | -0.76 | -0.46 | |
Graham Net | 5.24 | 3 | 0.42 | 0.23 | 1.49 | |
Working capital | 195.88M | 160.59M | 63.45M | 149.08M | 365.41M | |
Tangible asset value | 178.72M | 113.79M | -409.2M | 39.59M | 125.65M | |
Net current asset value | 178.55M | 111.68M | 15.68M | 23.72M | 107M | |
Invested capital | -0.11 | -0.18 | -0.12 | 0.86 | 0.94 | |
Average receivables | 0 | 0 | 0 | 18.85M | 66.26M | |
Average payables | 7.32M | 12.22M | 13.33M | 25.88M | 39.64M | |
Average inventory | 0 | 0 | 0 | 2.16M | 9.73M | |
Days sales outstanding | 0 | 0 | 0 | 275 | 127.9 | |
Days payables outstanding | 107K | 63.42K | 4.15K | 2.71K | 451.32 | |
Days of inventory on hand | 0 | 0 | 0 | 303.37 | 167.92 | |
Receivables turnover | 0 | 0 | 0 | 1.33 | 2.85 | |
Payables turnover | 0 | 0.01 | 0.09 | 0.13 | 0.81 | |
Inventory turnover | 0 | 0 | 0 | 1.2 | 2.17 | |
ROE | 0.4 | 0.38 | 0.33 | -1.81 | -1.25 | |
Capex per share | 0 | 0 | -0.01 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.56 | 2.19 | 1.07 | 1.23 | 1.51 | |
Net income per share | -1.54 | -0.26 | -1.54 | -1.32 | -2.08 | |
Operating cash flow per share | -0.63 | -0.13 | -1.27 | -1.14 | -0.64 | |
Free cash flow per share | -0.64 | -0.14 | -1.27 | -1.14 | -0.64 | |
Cash per share | 4.62 | 5.71 | 10.02 | 8.84 | 8.16 | |
Book value per share | 2.52 | 2.59 | 6.39 | 5.72 | 4.04 | |
Tangible book value per share | 0.91 | 1.01 | 4.82 | 4.3 | 2.65 | |
Share holders equity per share | 2.52 | 2.59 | 6.39 | 5.72 | 4.04 | |
Interest debt per share | 2.21 | 3.48 | 4.3 | 3.92 | 3.56 | |
Market cap | 3.35B | 2.66B | 3.13B | 3.29B | 3.77B | |
Enterprise value | 3.24B | 2.56B | 2.88B | 3.06B | 3.57B | |
P/E ratio | -12.55 | -59.31 | -11.67 | -13.24 | -9.55 | |
Price to sales ratio | 137.5 | 28.14 | 67.12 | 56.98 | 52.66 | |
POCF ratio | -121.58 | -457.18 | -56.63 | -61.5 | -124.07 | |
PFCF ratio | -120.79 | -451.67 | -56.49 | -61.07 | -124.04 | |
P/B Ratio | 30.59 | 23.8 | 11.24 | 12.22 | 19.72 | |
PTB ratio | 30.59 | 23.8 | 11.24 | 12.22 | 19.72 | |
EV to sales | 133.14 | 27.09 | 61.71 | 52.98 | 49.87 | |
Enterprise value over EBITDA | -60.43 | -516.21 | -50.19 | -49.29 | -30.3 | |
EV to operating cash flow | -117.73 | -440.21 | -52.07 | -57.18 | -117.49 | |
EV to free cash flow | -116.96 | -434.91 | -51.94 | -56.79 | -117.46 | |
Earnings yield | -0.02 | 0 | -0.02 | -0.02 | -0.03 | |
Free cash flow yield | -0.01 | 0 | -0.02 | -0.02 | -0.01 | |
Debt to equity | 0.86 | 1.32 | 0.66 | 0.69 | 0.94 | |
Debt to assets | 0.29 | 0.38 | 0.3 | 0.31 | 0.3 | |
Net debt to EBITDA | 1.98 | 19.9 | 4.4 | 3.72 | 1.7 | |
Current ratio | 2.54 | 3.02 | 4.52 | 4.46 | 3.63 | |
Interest coverage | -42.13 | -2.89 | -23.83 | 82.06 | 9.18 | |
Income quality | 0.45 | 0.52 | 0.82 | 0.86 | 0.31 | |
Dividend Yield | 0 | 0.02 | 0.01 | 0 | 0 | |
Payout ratio | 0 | -4.72 | -0.44 | -0.02 | 0 | |
Sales general and administrative to revenue | 4.01 | 0.56 | 1.12 | 0.95 | 0 | |
Research and developement to revenue | 0.6 | 0.19 | 0.44 | 0.5 | 0.43 | |
Intangibles to total assets | 0.21 | 0.18 | 0.11 | 0.11 | 0.11 | |
Capex to operating cash flow | 0.01 | 0.01 | 0 | 0.01 | 0 | |
Capex to revenue | -0.01 | 0 | 0 | -0.01 | 0 | |
Capex to depreciation | -0.09 | -0.04 | -0.1 | -0.21 | 0 | |
Stock based compensation to revenue | 0.44 | 0.14 | 0.34 | 0.26 | 0.26 | |
Graham number | 9.34 | 3.89 | 14.88 | 13.03 | 13.76 | |
ROIC | -0.3 | -0.03 | -0.14 | -0.14 | -0.25 | |
Return on tangible assets | -0.26 | -0.03 | -0.12 | -0.12 | -0.19 | |
Graham Net | 0.22 | 0.16 | 3.66 | 3.16 | 1.43 | |
Working capital | 149.08M | 203.8M | 404.71M | 397.1M | 365.41M | |
Tangible asset value | 39.59M | 43.41M | 210.26M | 202.57M | 125.65M | |
Net current asset value | 23.72M | 27.08M | 186.85M | 180.41M | 107M | |
Invested capital | 0.86 | 1.32 | 0.66 | 0.69 | 0.94 | |
Average receivables | 29M | 41.25M | 56.1M | 72.91M | 86.62M | |
Average payables | 25.72M | 37.19M | 39.36M | 36.03M | 34.89M | |
Average inventory | 3.21M | 6.13M | 8.6M | 9.62M | 12.56M | |
Days sales outstanding | 139.22 | 42.63 | 129.91 | 122.11 | 119.3 | |
Days payables outstanding | 1.52K | 426.06 | 840.67 | 400.92 | 496.22 | |
Days of inventory on hand | 169.71 | 94.57 | 181.06 | 137.58 | 184.62 | |
Receivables turnover | 0.65 | 2.11 | 0.69 | 0.74 | 0.75 | |
Payables turnover | 0.06 | 0.21 | 0.11 | 0.22 | 0.18 | |
Inventory turnover | 0.53 | 0.95 | 0.5 | 0.65 | 0.49 | |
ROE | -0.61 | -0.1 | -0.24 | -0.23 | -0.52 | |
Capex per share | 0 | 0 | 0 | -0.01 | 0 |
AXSM Frequently Asked Questions
What is Axsome Therapeutics, Inc. stock symbol ?
Axsome Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol AXSM
Is Axsome Therapeutics, Inc. buy or a sell ?
12 stock analysts have 12 predictions with a medium analyst target price of $81.83. The lowest prediction is $25 and the highest is $150
What is AXSM stock prediction ?
With a median analyst target price of $108.5, 2 stock analysts have made 2 forecasts in last 90 days. $108 is the lowest and $109 is the greatest projection.
What is Axsome Therapeutics, Inc. stock quote today ?
Axsome Therapeutics, Inc. stock price is $79.8 today.
Is Axsome Therapeutics, Inc. stock public?
Yes, Axsome Therapeutics, Inc. is a publicly traded company.